Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15869856 | 0.83 | FAAH (0.46) | FAAHELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL15884061 | 0.81 | FAAH (0.44) | FAAHELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL15884071 | 0.81 | FAAH (0.44) | FAAHELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL15862427 | 0.80 | TP53 (0.42) | — | |
| SCHEMBL2429277 | 0.80 | FAAH (0.60) | FAAHELANEMMP2MMP13MMP14 | |
| SCHEMBL15862451 | 0.79 | TP53 (0.39) | KMT2A | |
| SCHEMBL25210888 | 0.75 | CA1 (0.42) | FAAHELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL30474038 | 0.75 | CA1 (0.42) | FAAHELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL15884161 | 0.74 | HTR2A (0.42) | FAAHELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL15884059 | 0.74 | FAAH (0.41) | FAAHELANEKMT2ASCN9AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078899-B2 | Pyrazolyl-based carboxamides II | GRUENENTHAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9078899-B2 | Pyrazolyl-based carboxamides II | GRUENENTHAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| WO-2014108336-A1 | PYRAZOLYL-BASED CARBOXAMIDES II AS CRAC CHANNEL INHIBITORS | Grünenthal GmbH (DE) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194452-A1 | Pyrazolyl-Based Carboxamides II | Grünenthal GmbH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194452-A1 | Pyrazolyl-Based Carboxamides II | Grünenthal GmbH (DE) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194452-A1 | Pyrazolyl-Based Carboxamides II | AADAC, VDAC2, NLRP3 | FAAH 1408/4885ELANE 1111/4885GABRG2 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.